Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews published molecular biology and gerontology research. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your diet, supplement regimen, or any health-related decision.

In August 2006, Shinya Yamanaka and Kazutoshi Takahashi published a paper in Cell showing that four transcription factors — Oct4, Sox2, Klf4, and c-Myc, now abbreviated as the OSKM factors — were sufficient to reprogram adult mouse fibroblasts into cells that behaved like embryonic stem cells. Within a year, Yamanaka’s group and James Thomson’s laboratory at the University of Wisconsin had independently applied the same approach to human cells. By 2012, the discovery had earned Yamanaka and John Gurdon the Nobel Prize in Physiology or Medicine.

The original framing for this work was regenerative medicine: produce patient-matched pluripotent cells without embryo use, potentially generating replacement tissues without immune rejection. That application has continued through Yamanaka’s Center for iPS Cell Research and Application (CiRA) at Kyoto University, which has contributed foundational work on clinical iPS cell protocols and safety validation over the intervening years.

The aging biology angle arrived separately and is distinct from the regenerative medicine application. Researchers examining the reprogramming process noticed something about what the OSKM factors do to the epigenome: when cells are fully reprogrammed to induced pluripotent stem cells (iPSCs), their epigenetic age — as measured by DNA methylation clock methods — is reset toward a youthful configuration. The question that followed was whether a partial version of that reset, not enough to erase cell identity but enough to shift the epigenome in a younger direction, was biologically achievable and separable from the dedifferentiation effects.

TL;DR

• Yamanaka’s 2006 Cell paper established that OSKM factors (Oct4, Sox2, Klf4, c-Myc) can fully reprogram somatic cells to pluripotency; full reprogramming erases cell identity and carries oncogenic risk, particularly from sustained c-Myc overexpression
• Partial or cyclic reprogramming — transient, pulsed OSKM expression — appears to reset epigenetic age in cell culture and specific mouse tissue systems without driving cells to full dedifferentiation
• Ocampo et al. (2016, Cell) demonstrated cyclic OSKM expression in a progeria mouse model was associated with reduced aging markers and extended lifespan in that genetic accelerated aging context; this is a monogenic disease model, not standard aging
• A 2020 Nature study from Sinclair’s laboratory showed OSK expression (without c-Myc) in aged retinal ganglion cells was associated with improved visual function and measurable epigenetic age reduction in mouse optic nerve injury models
• CiRA at Kyoto University has applied methylation clock methodology to map the reprogramming trajectory in molecular detail, contributing to how the field measures biological age in this context
• Calibration: partial reprogramming research is at animal model and cell culture stage as of mid-2026; no human clinical trials for aging applications have been completed; commercial products describing “epigenetic reprogramming” mechanisms are running substantially ahead of the published evidence

The dedifferentiation problem with full OSKM expression

Full reprogramming works by systematically erasing the epigenetic memory that defines cell identity. The process involves widespread DNA demethylation, chromatin remodeling, and reactivation of pluripotency gene networks that are silenced in differentiated adult cells. That erasure is precisely what resets the epigenetic age toward an embryonic-equivalent state. It is also the mechanism through which a liver cell loses its liver identity, and a skin cell loses its skin identity, in favor of the undifferentiated state that characterizes iPSCs.

For regenerative medicine applications, this is the intended outcome: produce a cellular blank slate that can be re-directed toward any tissue type the researcher needs. For aging applications in living organisms — where the goal is to make aged cardiac or neural tissue more functionally youthful without first converting it to an undifferentiated mass — full reprogramming is not a viable approach.

The c-Myc factor introduces an additional constraint. It is a proto-oncogene, and sustained overexpression in vivo is associated with tumor formation in animal models. Earlier iPSC protocols that included c-Myc in constitutively expressed systems showed elevated teratoma rates. Clinical-grade protocols developed at CiRA and peer institutions subsequently moved toward c-Myc-free approaches or tightly regulated expression systems to address this risk for regenerative medicine contexts. For partial reprogramming research, a subset of groups have adopted OSK combinations without c-Myc to reduce oncogenic risk, accepting that the remaining three factors may produce slower or different epigenetic effects.

The partial reprogramming hypothesis attempts to retain the epigenetic reset property while containing the dedifferentiation cost. In pulsed or cyclic protocols, OSKM factors are expressed for short windows — typically days — and then removed. The rationale is that the early phase of reprogramming primarily affects aging-associated epigenetic marks, while the full erasure of differentiated cell identity requires sustained expression over a longer period. Whether this window is actually cleanly separable from dedifferentiation, and across which tissue types and delivery conditions, is what the experimental evidence is working through.

Key experimental milestones

The 2016 Cell paper from Ocampo, Muñoz-Cánoves, and Izpisua Belmonte at the Salk Institute was the first substantial animal evidence. Working with a genetically engineered mouse model of Hutchinson-Gilford Progeria Syndrome — a condition caused by a mutant form of lamin A (progerin) that produces severe accelerated aging phenotypes through disrupted nuclear lamina architecture — they introduced an inducible OSKM transgene controlled by a doxycycline-regulated Tet-on system. Cyclic OSKM expression — four days on, three days off — in progeroid mice was associated with improved tissue histology across multiple organs, reduced markers of cellular senescence, and extended lifespan relative to non-treated progeroid mice. Methylation clock analysis found reduced epigenetic age in treated tissues compared to untreated controls at matched timepoints.

The progeria caveat is specific and worth stating plainly: Hutchinson-Gilford Progeria Syndrome is a monogenic disease driven by abnormal nuclear architecture and accelerated DNA damage accumulation, a molecular context that differs from standard aging in important respects. Progeroid mice undergoing cyclic reprogramming are not equivalent to normally aged mice receiving the same treatment. These results establish that OSKM pulsing can affect aging-associated molecular signatures in a living mammal under controlled conditions; they do not establish that the effects generalize to non-progeroid aging organisms without independent demonstration.

The 2020 Nature paper from Lu and colleagues at Sinclair’s laboratory at Harvard Medical School addressed a different and more accessible tissue system: retinal ganglion cells. Working with aged mice and models of optic nerve injury designed to reproduce aspects of glaucoma-related damage, the team delivered OSK factors (without c-Myc) through adeno-associated virus (AAV) targeted to retinal ganglion cells. After OSK expression, aged retinal ganglion cells showed reduced epigenetic age on DNA methylation clock measures, improved electrophysiological responses to light stimuli, and — in the optic nerve injury models — improved axon regrowth and visual function relative to controls that received a non-expressing viral vector.

The retinal ganglion cell system is both the strength and the scope boundary of this evidence. The eye is anatomically accessible, the targeted cell population is well-characterized, and visual function can be measured with electrophysiological precision. The results establish that OSK expression in this tissue, through this delivery system, is associated with the reported functional and epigenetic effects in the specific experimental contexts tested. Generalization to other tissues — particularly those less accessible to localized AAV delivery, where dedifferentiation risk profiles may differ, or where age-associated pathology has a different molecular basis — requires separate experimental demonstration.

Subsequent work from Altos Labs-affiliated researchers and independent groups has extended partial reprogramming experiments to additional tissue contexts in mice — including liver, kidney, and muscle — with varying results. The broader tissue evidence as of 2026 is accumulating but remains at the animal model stage, with ongoing work addressing consistency across tissues and the safety profile of different factor combinations and expression durations.

Japan’s research contributions: CiRA and the reprogramming trajectory

The Center for iPS Cell Research and Application at Kyoto University occupies a central position in this research area because the OSKM factors themselves originated there. Yamanaka’s continued research direction at CiRA has addressed the molecular characterization of reprogramming trajectories with DNA methylation clock resolution — mapping precisely how epigenetic age changes through the sequential stages of factor exposure, from initial chromatin opening events through the late phases where cell identity erosion becomes measurable.

This measurement work matters for partial reprogramming research because the epigenetic clock is the primary instrument used to assess whether an intervention has shifted biological age. The application of Horvath clock and GrimAge methylation analysis to reprogramming trajectories in cell culture was developed substantially through contributions from CiRA-affiliated researchers and their collaborators. The operational definition of “partial” reprogramming — how much epigenetic age change is achievable before cell identity markers begin to shift — depends on these measurement tools for its experimental meaning.

Yamanaka joined Altos Labs as Institute President in 2022, bringing CiRA’s institutional expertise into the commercial partial reprogramming research structure. The Japan Agency for Medical Research and Development (AMED) has continued funding epigenetic mechanism research in aging through grants spanning CiRA and university hospital systems, with particular focus on how the aging-associated chromatin state interacts with early reprogramming factor exposure — the window in which partial reset might be achievable before the identity-erasing phase of reprogramming proceeds.

The epigenetic clock work covered in the epigenetic clock and Japanese longevity article provides the methodological context for how these biological age measurements are made and what they mean at the population level — relevant background for understanding how the same tools are applied in the reprogramming context, where the question shifts from “what diet and lifestyle factors are associated with slower clock aging?” to “can deliberate factor expression reset clock age at a cellular level?”

Where the research stands as of mid-2026

Partial reprogramming has attracted substantial investment from longevity-focused organizations. Altos Labs (founded 2022) is the highest-profile, with Yamanaka as Institute President and a scientific team drawn from leading aging biology laboratories. Retro Biosciences (founded 2021) and several other biotechnology organizations are pursuing partial reprogramming for aging applications. The funding and scientific talent in this field are significant by early-stage research standards.

The evidence base as of mid-2026 consists of:

• Cell culture data across multiple cell types showing that transient OSKM or OSK exposure is associated with epigenetic age reduction on methylation clock measures
• Animal model data in specific tissue contexts showing functional correlates consistent with epigenetic rejuvenation in those tissues
• Early-stage animal evidence in broader aging contexts from multiple research groups
• No completed human clinical trials for aging applications

Translation to human therapeutic applications requires addressing several open problems: delivery systems capable of reaching target tissues in humans at therapeutic scale; reliable on/off control mechanisms that limit expression duration in vivo without residual factor activity; safety characterization of oncogenic risk from partial OSKM expression across diverse human tissue types and delivery conditions; and regulatory frameworks for interventions involving transcription factor delivery to human tissues. These are substantive engineering and safety challenges that account for why the timeline from current evidence to human clinical applications is measured in years to decades rather than months.

What the evidence does not establish

That oral supplements replicate epigenetic age reset. Multiple supplement products describe their mechanism of action in terms that invoke epigenetic reprogramming or biological age reduction. The partial reprogramming evidence base involves controlled gene expression of specific transcription factors through viral or genetic delivery systems. There is no established biological mechanism by which an orally consumed compound replicates the chromatin-level effects of OSKM factor delivery. The gap is not a matter of dosage — it is a category difference in how the intervention engages with cellular machinery.

That the retinal ganglion cell findings generalize to systemic aging. Lu et al.’s results are in a specific tissue, delivered through a specific vector, measured in specific experimental models. They establish proof of concept for the approach in that context; they do not establish that partial reprogramming produces comparable effects throughout the tissues of an aging organism.

That progeria model results apply to standard aging. The Ocampo et al. findings are in a genetic disease model with a specific molecular mechanism — not in normally aged animals. The biological context differs from standard aging in ways that affect how the results generalize, and independent validation in standard aging models is the appropriate evidentiary standard before extending the progeria findings to the broader aging process.

That Altos Labs or related commercial programs have established human efficacy. These programs represent serious scientific investment in partial reprogramming research; they have not published completed human trial data for aging applications as of mid-2026. Following their published output over coming years is the appropriate way to track what the evidence shows.

That commercial epigenetic clock tests plus lifestyle interventions constitute a partial reprogramming protocol. Methylation clock measurements are research tools applied to population-level questions. An individual test result does not indicate whether partial reprogramming is indicated, feasible, or safe, and no consumer-accessible intervention replicates the controlled factor expression studied in the published animal literature.

Reading further

David Sinclair’s Lifespan presents the information theory of aging — the hypothesis that epigenetic information loss is itself a primary driver of biological aging rather than merely a correlate — and provides the theoretical framing through which partial reprogramming becomes a central research priority. Available on Amazon. Andrew Steele’s Ageless covers the broader landscape of longevity research approaches, including reprogramming alongside senolytics, NAD+ biology, and telomere interventions, with calibration on where each stood in clinical translation at the time of writing. Available on Amazon.

For the primary literature, Ocampo et al. 2016 Cell and Lu et al. 2020 Nature are both accessible through PubMed and are the appropriate starting points for readers who want to assess the experimental evidence directly. The CiRA research page at Kyoto University provides updates on Yamanaka’s ongoing laboratory work.

Those interested in where the adjacent molecular biology connects to diet and lifestyle — a better-evidenced area for consumer-level consideration — will find the relevant evidence reviewed in the epigenetic clock and Japanese longevity article and the NAD+ precursor evidence in the sirtuins and NAD+ article. The cellular senescence and senolytics research — a parallel mechanistic track in the aging biology field — is covered in the cellular senescence and senolytics article. For additional books on aging science and longevity biology for those tracking this research area, a range of titles is available on Amazon.

---

Research cluster: Epigenetic Clock and Japanese Longevity: Horvath, Diet, and Biological Age Evidence | Cellular Senescence and Senolytics: p16/SASP Mechanisms and Japan’s Research Contribution | Sirtuins, NAD+, and Caloric Restriction: Molecular Pathway Research | mTOR, Caloric Restriction, and Aging | Longevity Genes vs. Lifestyle: Epigenetic Clocks and Centenarian Genetics | Yoshinori Ohsumi’s Nobel and the Fasting Question: What the Autophagy Research Shows